U.S. Health Officials Move Quickly to Deploy Medical A.I. Despite Concerns
By Christina Jewett,
The New York Times
| 09. 14. 2026
The Trump administration is accelerating efforts to make artificial intelligence an integral part of medical care in the United States, throwing the resources and support of the federal government into projects that deploy A.I. agents to diagnose and prescribe treatments to patients.
The multifront effort at the Department of Health and Human Services has raised concerns among some officials over the past few months that change is moving too quickly, with inadequate evidence of the technology’s safety and effectiveness, according to people who have been involved the discussions. They also worry about outsized influence of Silicon Valley investors that have previously played little role in federal health policy.
Vinod Khosla, a billionaire Silicon Valley venture capitalist whose son has a health care A.I. company, has been particularly influential in conversations with top health department officials, according to people close to the matter. Those officials include Dr. Mehmet Oz, the head of Medicare and Medicaid. Chris Klomp, who faces a confirmation hearing this week to be the second-in-command at the health department, said on a podcast in May that the use...
Related Articles
By Carl Zimmer, The New York Times | 10.20.2026
For the first time, scientists say they have used viruses designed by artificial intelligence to treat a human patient.
Researchers announced on Tuesday that they had administered the virus, known as a phage, to a patient suffering from a deadly...
By Noah Fromson, HealthLab | 10.19.2026
Gene therapy is no longer the future of medicine — it’s reality. Treatments that replace, silence or edit genes are already changing clinical care.
There are more than 6,000 rare genetic disorders but only a fraction currently have treatable targets...
By Roxanne Khamsi, The Atlantic | 10.16.2026
In recent months, news came out about several distressing cases that have underscored the risks of gene therapy, which delivers DNA to a patient’s cells to treat disease. All of these cases have one thing in common that’s not apparent...
By Rebecca Roberts, The Scientist | 10.11.2026
Heritable genome editing in human embryos is once again under intense scrutiny after the publication of an opinion piece in Trends in Genetics at the end of last month.1 In the paper, Cathy Tie, the founder and chief...